Pharvaris (NASDAQ:PHVS) Sees Unusually-High Trading Volume – What’s Next?

Pharvaris N.V. (NASDAQ:PHVS) saw strong trading volume on Friday . 686,686 shares traded hands during trading, an increase of 189% from the previous session’s volume of 237,227 shares.The stock last traded at $30.92 and had previously closed at $31.63.

Analysts Set New Price Targets

A number of brokerages recently weighed in on PHVS. Citizens Jmp decreased their price objective on shares of Pharvaris from $75.00 to $74.00 and set a “market outperform” rating for the company in a report on Wednesday, May 13th. Wall Street Zen upgraded Pharvaris from a “strong sell” rating to a “sell” rating in a research note on Saturday, May 16th. HC Wainwright restated a “buy” rating and issued a $60.00 price target on shares of Pharvaris in a research note on Tuesday, March 3rd. Royal Bank Of Canada dropped their price objective on Pharvaris from $52.00 to $51.00 and set an “outperform” rating on the stock in a research report on Monday, April 6th. Finally, Wedbush lifted their price objective on Pharvaris from $41.00 to $42.00 and gave the stock an “outperform” rating in a report on Tuesday, April 7th. Ten equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $49.18.

Pharvaris Stock Down 1.7%

The company has a market cap of $2.03 billion, a PE ratio of -9.78 and a beta of -2.35. The company’s fifty day moving average is $29.14 and its 200-day moving average is $27.28.

Pharvaris (NASDAQ:PHVS) last released its quarterly earnings results on Tuesday, May 12th. The company reported ($0.70) earnings per share for the quarter, beating the consensus estimate of ($0.82) by $0.12. Equities research analysts expect that Pharvaris N.V. will post -3.25 EPS for the current fiscal year.

Insider Buying and Selling

In other news, Director Johannes Gerardus Chri Schikan sold 29,070 shares of the stock in a transaction that occurred on Thursday, April 30th. The shares were sold at an average price of $30.32, for a total value of $881,402.40. Following the transaction, the director owned 355,167 shares in the company, valued at $10,768,663.44. This represents a 7.57% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Peng Lu sold 15,000 shares of the business’s stock in a transaction that occurred on Thursday, April 30th. The shares were sold at an average price of $30.24, for a total transaction of $453,600.00. Following the sale, the insider owned 66,083 shares of the company’s stock, valued at $1,998,349.92. This trade represents a 18.50% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 209,948 shares of company stock valued at $6,268,141 in the last 90 days. Insiders own 11.84% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of PHVS. GF Fund Management CO. LTD. purchased a new stake in shares of Pharvaris in the 4th quarter worth $35,000. JPMorgan Chase & Co. lifted its position in Pharvaris by 30.6% during the second quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock valued at $59,000 after purchasing an additional 783 shares in the last quarter. China Universal Asset Management Co. Ltd. bought a new stake in Pharvaris during the third quarter valued at about $75,000. Barclays PLC bought a new stake in Pharvaris during the fourth quarter valued at about $77,000. Finally, Mirae Asset Global Investments Co. Ltd. purchased a new stake in Pharvaris in the fourth quarter worth about $86,000.

Pharvaris Company Profile

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.